Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Company profile
Ticker
SNGX
Exchange
Website
CEO
Dr. Christopher J. Schaber Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Enteron Pharmaceuticals, Inc. • Orasomal Technologies Inc. • Soligenix BioPharma Canada Incorporated • Soligenix UK Limited • Soligenix NE B.V. • Soligenix Biopharma HI, Inc. ...
IRS number
411505029
SNGX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
11 Oct 24
424B5
Prospectus supplement for primary offering
16 Aug 24
8-K
Other Events
16 Aug 24
424B3
Prospectus supplement
9 Aug 24
424B3
Prospectus supplement
9 Aug 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
EFFECT
Notice of effectiveness
5 Aug 24
8-K
Entry into a Material Definitive Agreement
25 Jul 24
S-1
IPO registration
24 Jul 24
8-K
Entry into a Material Definitive Agreement
9 Jul 24
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.41 mm | 9.41 mm | 9.41 mm | 9.41 mm | 9.41 mm | 9.41 mm |
Cash burn (monthly) | (no burn) | 312.37 k | 581.56 k | 672.28 k | 639.28 k | 647.90 k |
Cash used (since last report) | n/a | 1.17 mm | 2.18 mm | 2.52 mm | 2.40 mm | 2.43 mm |
Cash remaining | n/a | 8.24 mm | 7.23 mm | 6.89 mm | 7.01 mm | 6.98 mm |
Runway (months of cash) | n/a | 26.4 | 12.4 | 10.2 | 11.0 | 10.8 |
Institutional ownership, Q2 2024
30.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 26.86 mm |
Total shares | 688.34 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Altamont Phamaceutical | 678.34 k | $1.05 mm |
ONB Old National Bancorp | 10.00 k | $25.80 mm |
Albion Financial | 1.00 | $3.00 k |
Trust Co Of Vermont | 1.00 | $3.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Dec 23 | Zeldis Jerome B | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Parks Diane L. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Rubin Robert J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Lapointe Anthony Gregg | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
8 Dec 23 | Jonathan L. Guarino | Option Common Stock | Grant | Acquire A | No | No | 0.67 | 90,000 | 60.30 k | 90,000 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
7 Oct 24
Soligenix to Present New Findings on HyBryte for Treating T-Cell Lymphoma at EORTC Meeting
7 Oct 24
12 Health Care Stocks Moving In Thursday's Intraday Session
3 Oct 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
3 Oct 24
Soligenix Establishes Partnership Agreement With Sterling Pharma Solutions To Optimize, Implement A Commercially Viable, Scalable Production Technology For Synthetic Hypericin
3 Oct 24
Press releases
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
22 Oct 24
Soligenix Invited to Present at Upcoming Investor Conferences
16 Oct 24
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
7 Oct 24
Soligenix Announces Partnership with Sterling Pharma Solutions
3 Oct 24
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
20 Sep 24